From Silicon to Sentience: mimik Unveils Ubiquitous AI Execution Fabric with AMD Platforms for the Agentic Economy
mimik your ROI for AI
With mimik's platform pre-integrated across AMD-based systems, enterprises and developers can achieve out-of-the-box agentic deployment today, with the certainty to deliver intelligence wherever it's needed in the business to drive rapid growth. The result is a context-aware, dynamically discoverable, adaptive, and resilient compute fabric, with built-in zero-trust security, network offline-first capability, and seamless multi-cloud integration when agentic AI requires it. Developers can start building and deploying agentic workflows immediately, accelerating solution delivery without needing to rebuild infrastructure.
'This collaboration marks a turning point,' said Fay Arjomandi, Founder and CEO of mimik. 'We're not retrofitting legacy AI. We're enabling, giving developers and enterprises a frictionless way to adopt and scale agentic AI where compute is fluid, intelligence is choreographed, and AI execution is embedded into every layer of infrastructure.'
With this integration, AMD hardware becomes an execution-ready environment for real-time AI, optimized for business-critical workloads across diverse environments.
AMD shares this vision of an adaptive, agent-ready future. 'Our collaboration with mimik enables a new generation of AI systems that are responsive, distributed, and production-ready,' said Ramine Roane, corporate vice president, Artificial Intelligence Group, AMD. 'By embedding mimik's execution environment across AMD platforms, from the smallest cameras and robots to the largest server, we're enabling real-time AI that's dynamic, sovereign, and built for scale. This is the future of AI compute: ubiquitous, intelligent, enterprise and developer ready.'
mimik's software enablers, pre-integrated across AMD platforms and built on an open API model, allow developers and enterprises to deploy agentic workflows out-of-the-box, locally or in coordination with other nodes. The result is a dynamically choreographed mesh of AI agents operating across AMD's device-first continuum compute fabric that is context-aware, resilient, offline-first, and cloud-capable when needed. This is the execution foundation of the Agentic Economy, ready to scale real-world impact, today.
Watch the demo video to see how mimik with AMD deliver Physical AI across the device-first continuum: https://www.youtube.com/watch?v=7JEtOYap_J0.
About mimik:
mimik powers the Agentic Economy with Agentix-Native software that turns everyday devices into intelligent collaborative systems. Its software platform enables real-time inference across smartphones, cameras, drones, robots, machines, and servers. By creating a Device-First AI continuum across endpoint devices and the cloud, mimik gives way to enterprises to operationalize agentic AI, scale intelligence, and optimize performance and cost.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
San Francisco Chronicle
an hour ago
- San Francisco Chronicle
Investcorp: Fiscal Q4 Earnings Snapshot
NEW YORK (AP) — NEW YORK (AP) — Investcorp Credit Management BDC, Inc. (ICMB) on Tuesday reported a loss of $434,000 in its fiscal fourth quarter. The New York-based company said it had a loss of 3 cents per share. Earnings, adjusted for investment costs, were 4 cents per share. The specialty finance company posted revenue of $4.5 million in the period.
Business Wire
2 hours ago
- Business Wire
Figma and Motiff Reach Global Settlement in Intellectual Property Protection Lawsuits
SAN FRANCISCO--(BUSINESS WIRE)-- Figma and Motiff announced today that the companies have reached an agreement to resolve their intellectual property disputes in the U.S. and Singapore. Under the settlement agreement, Motiff will cease selling its current Motiff Editor Tool and will not sell any future products derived from it, globally, with the exception of mainland China. In September 2024, Figma filed a U.S. lawsuit for breach of contract and copyright infringement against Motiff and its affiliates. On the same day that Figma filed its U.S. suit, it also sued Motiff in Singapore for copyright infringement and trademark infringement. Figma and Motiff have mutually agreed to settle both lawsuits. Under the settlement agreement, Motiff will cease selling its current Motiff Editor Tool and will not sell any future products derived from it, globally, with the exception of mainland China. In mainland China, Motiff may continue to sell its current Motiff Editor Tool for one year, while it reengineers and redesigns the product. Motiff has also agreed to reimburse Figma's legal expenses. 'Figma is singularly focused on building the best possible product for our users. We welcome fair competition and strongly believe that no one should be allowed to copy our or others' IP to gain an advantage. We are pleased to have reached a global settlement that aligns with Figma's values and allows us to keep building for our customers and community without distraction,' said a Figma spokesperson. 'Motiff is equally pleased to have reached a compromise global settlement with Figma that will allow us to focus our efforts on Motiff's AI 2.0 product. Motiff is committed to bringing AI value to our users,' said a Motiff spokesperson. The agreement took effect on July 23, 2025.
Business Wire
2 hours ago
- Business Wire
New Irish Healthtech Firm Phyxiom Set to Transform Asthma and COPD Management
DUBLIN--(BUSINESS WIRE)-- Phyxiom, a pioneering digital healthcare company, today announced its official launch, bringing transformative technology developed through extensive clinical research led by globally recognised respiratory specialist, Professor Richard Costello (RCSI University of Medicine and Health Sciences and Beaumont Hospital). Built upon groundbreaking studies published in Lancet Respiratory Medicine and validated by health economists, Phyxiom's platform provides clinicians with precise, real-time data to significantly enhance asthma and Chronic Obstructive Pulmonary Disease (COPD) management. Co-founded by experienced tech executive Grace O'Donnell as Chief Executive Officer and healthcare professional Elaine Mac Hale as Clinical Operations Director, along with Prof Costello, Phyxiom is a spin-out company from RCSI. Based on a strong foundational IP portfolio developed under an Enterprise Ireland (EI) Commercialisation Fund award the company has recently achieved EI High Potential Start- Up (HPSU) status. O'Donnell and Mac Hale lead Phyxiom's day-to-day operations, driving forward its mission to revolutionise respiratory healthcare through advanced digital solutions. Professor Richard Costello, Chief Medical Officer at Phyxiom and Professor of Respiratory Medicine at RCSI, explained the science behind the innovation: 'Our research, spanning over a decade, has conclusively demonstrated that digitally-informed treatment significantly reduces medication use, prevents unnecessary hospitalisations, and ultimately lowers healthcare costs. By providing clinicians with objective, real-time insights into lung function and medication adherence, Phyxiom fundamentally improves diagnosis accuracy and treatment outcomes.' Phyxiom's technology is already operational across 13 Health Service Executive (HSE) asthma clinics in Ireland, processing nearly 350 patients to date, with plans to expand further and engage Irish private health insurers in 2025. Grace O'Donnell, CEO, said: 'Elaine and I are incredibly proud to lead this exciting RCSI spin-out company into the commercial market. We are passionate about using Richard's groundbreaking research as the foundation to deliver transformative, patient-centric healthcare solutions, significantly improving quality of life for patients suffering from uncontrolled asthma and COPD.' Elaine Mac Hale, Clinical Operations Director, added: 'Phyxiom seamlessly integrates into existing healthcare systems, ensuring minimal disruption to clinicians' workflows. Our evidence-based approach empowers healthcare providers with the insights needed to deliver personalised, effective, and efficient patient care.' Following its successful Irish rollout, Phyxiom is expanding into the UK market in H1 2026 and plans a US launch in 2027, supported by established partnerships and integration with leading electronic health record systems. Phyxiom's launch marks a significant milestone in Ireland's healthtech landscape, highlighting Irish innovation on the global healthcare stage. Those interested in learning more about Phyxiom, can visit the website here: About RCSI University of Medicine and Health Sciences RCSI University of Medicine and Health Sciences is ranked first in the world for its contribution to UN Sustainable Development Goal 3, Good Health and Well-being, in the Times Higher Education (THE) University Impact Rankings 2025. Founded in 1784 as the Royal College of Surgeons in Ireland with responsibility for training surgeons in Ireland, today RCSI is an innovative, not-for-profit, international university exclusively focused on driving improvements in human health worldwide through education, research and engagement. RCSI is among the top 300 universities worldwide in the World University Rankings (2025) and has been awarded Athena Swan Bronze accreditation for positive gender practice in higher education. In 2026, RCSI will open a new public engagement space, dedicated to health and well-being, at 118 St Stephen's Green in Dublin city centre. The space is designed to engage the public in dialogue about living longer, healthier and happier lives through dynamic events and exhibitions. Our aim is to bridge the gap between health sciences research, professional expertise, and public understanding, empowering people to make informed decisions about their health. Visit the RCSI MyHealth Expert Directory to find the details of our experts across a range of healthcare issues and concerns. Recognising their responsibility to share their knowledge and discoveries to empower people with information that leads them to better health, these clinicians and researchers are willing to engage with the media in their area of expertise.
